# Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

> **NCT00803010** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 74 (actual)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** Tacrolimus (TAC)
- **DRUG:** Methotrexate (MTX)
- **DRUG:** Rapamycin (RAPA)

## Key facts

- **NCT ID:** NCT00803010
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2015-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00803010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00803010, "Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00803010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*